Phase II Trial of Tamoxifen and Bortezomib in Patients With Recurrent High-Grade Gliomas.

Trial Profile

Phase II Trial of Tamoxifen and Bortezomib in Patients With Recurrent High-Grade Gliomas.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Bortezomib (Primary) ; Tamoxifen (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2013 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 09 Jul 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top